March 12 - 15, 2020
Westin Denver Downtown
Abstract submission deadline: Tuesday, December 31
Advance registration deadline: Monday, February 3
Thursday, March 12, 2020
Friday, March 13, 2020
Saturday, March 14, 2020
Sunday, March 15, 2020
Thursday, March 12
Welcome and Opening Keynote Addresses6:30-8 p.m.
Opening Keynote Addresses
Ecology and evolution in control and cure of metastatic cancersRobert A. Gatenby, Moffit Cancer Center, Tampa, Florida
Title to be announcedCharlie Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom
Opening Reception8-10 p.m.
Top of pageFriday, March 13
Continental Breakfast7-8 a.m.
Plenary Session 1: Longitudinal Dissection of Resistance EvolutionSession Chair: Marco Gerlinger, The Institute of Cancer Research, London, United Kingdom8-10 a.m.
Title to be announcedMarco Gerlinger
Investigating clonal dynamics and evolution of metabolic vulnerabilities in chemoresistant triple negative breast cancer*Gloria Echeverria, Baylor College of Medicine, Houston, Texas
Novel cancer therapeutic approachesJeffrey A. Engelman, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
Longitudinal molecular trajectories of diffuse glioma in adults*Floris Barthel, The Jackson Laboratory, Farmington, Connecticut
Title to be announcedTrever G. Bivona, University of California San Francisco, San Francisco, California
Panel Discussion: Genetic, Epigenetic, and Functional Heterogeneity in Cancer: Which One(s) Can We Call Evolution?Panel Moderator: Robert Gillies, Moffitt Cancer Center, Tampa, Florida10:30-11:30 a.m.
Panelists:Andrew Feinberg, Johns Hopkins School of Medicine, Baltimore, MarylandRobert Gatenby, Moffit Cancer Center, Tampa, FloridaKornelia Polyak, Dana-Farber Cancer Institute, Boston, MassachusettsCharlie Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom
Poster Session A / Lunch11:30 a.m.-2 p.m.
Plenary Session 2: Clonal Evolution Part ISession Chair: Robert J. Gillies, Moffitt Cancer Center, Tampa, Florida2-4 p.m.
Somatic mutation and clonal expansions in human tissuesIñigo Martincorena, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Stem cell dynamics in developing and established cancers in the gutLouis Vermeulen, Academic Medical Center, Amsterdam, Netherlands
In cancer as in real estate, location matters: The role of extrachromosomal oncogene amplification in cancerPaul S. Mischel, University of California San Diego, San Diego, California
Selecting for a glycolytic phenotypeRobert J. Gillies
Plenary Session 3: Generation of Genomic and Epigenomic DiversitySession Chair: Rong Li, Johns Hopkins University, Baltimore, Maryland4:15-6:15 p.m.
Natural selection of cancer cells in a stochastic epigenetic landscapeAndrew P. Feinberg, Johns Hopkins School of Medicine, Baltimore, Maryland
Genomic transcriptional diversity induced by UV exposure: molecular drivers of squamous cell carcinoma development*Leticia Tordesillas, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
APOBEC3A catalyzes mutation and drives carcinogenesis in vivoReuben S. Harris, University of Minnesota, Minneapolis Minnesota
Epigenetically regulated DNA rereplication as a precursor to inherited gene amplification*Joshua Black, University of Colorado, Denver, Colorado
The DNA damageome: A cancer evolvability protein network Discovered in E. coliSusan Rosenberg, Baylor College of Medicine, Houston, Texas
Evening Off / Dinner on Own6:15 p.m.
Top of pageSaturday, March 14
Continental Breakfast7-8 a.m.
Plenary Session 4: Microenvironmental SelectionSession Chair: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts8-10 a.m.
Ageing, tissue ecology and the evolution of cancer within usJames V. DeGregori, University of Colorado, Aurora, Colorado
Breast tumor evolution: the role of the microenvironmentKornelia Polyak
Understanding how age-dependent inflammation can lead to oncogenic adaptation in lung cancer*Catherine Danis, University of Colorado, Denver, Colorado
Cancer evolution in the lens of single cell multi-omicsDan A. Landau, Meyer Cancer Institute, Cornell University, New York, New York
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence Part ISession Chair: Andriy Marusyk, Moffitt Cancer Center, Tampa, Florida10:30 a.m.-12:30 p.m.
Title to be announcedMichael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Title to be announcedMax Diehn, Stanford University, School of Medicine, Stanford, California
Multimodal integration of scRNA-seq and longitudinal treatment-response data into a mathematical model of chemotherapeutic resistance dynamics*Kaitlyn Johnson, The University of Texas at Austin, Austin, Texas
Resistance to targeted therapies as a gradual, multifactorial adaptation to inhibitor specific selective pressuresAndriy Marusyk
Lunch on Own12:30-2 p.m.
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence Part IISession Chair: Ivana Bozic, University of Washington, Seattle, Washington2-5 p.m.
Title to be announcedIra Mellman, Genentech, Inc., South San Francisco, California
Title to be announcedJennifer Wargo, The Unviersity of Texas MD Anderson Cancer Center, Houston, Texas
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence Part II (continued)
Emergent cellular ecosystems in melanoma revealed by single cell analysisArjun Raj, University of Pennsylvania, Philadelphia, Pennsylvania
Heterogeneous clonal dynamics of leukemia progression and chemotherapy response in patient-derived xenograft models*Rong Lu, University of Southern California, Los Angeles, California
Evolutionary dynamics of cancer and its response to therapyIvana Bozic
Extensive subclonal mutational diversity in human colorectal cancer (CRC) and its significance*Robert Beckman, Georgetown University, Washington D.C.
Poster Session B / Reception5-7 p.m.
Dinner on Own7 p.m.
Sunday, March 15
Plenary Session 6: Evolutionary Guided (Adaptive) Therapy to Prevent Emergence of ResistanceSession Chair: Carlo C. Maley, Arizona State University, Tempe, Arizona8-10 a.m.
Karyotype heterogeneity driving rapid evolutionary adaptationRong Li, Johns Hopkins University, Baltimore, Maryland
Adaptive mutability of colorectal cancer in response to targeted therapiesAlberto Bardelli, Candiolo Cancer Institute IRCCS, University of Turin, Italy
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap*Kevin Lin, Duke University School of Medicine, Durham, North Carolina
Explorations in adaptive therapyCarlo C. Maley
Plenary Session 7: Clonal Evolution Part IISession Chair: Christina Curtis, Stanford University School of Medicine, Stanford, California10:30 a.m.-12:30 p.m.
Title to be announcedAndrea Sottoriva, The Institute of Cancer Research, London, United Kingdom (ICR)
Opposing evolutionary pressures drive clonal evolution and health outcomes in the aging blood system*Kimberly Skead, Ontario Institute for Cancer Research, Toronto, Canada
Title to be announcedNicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas
The landscape of somatic mutations in normal human cells*Luiza Moore, Wellcome Sanger Institute, Cambridge, United Kingdom
Towards quantifying and forecasting tumor evolutionChristina Curtis
Closing Remarks12:30 p.m.
*Short talk from proffered abstracts
Top of page